Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Modulation of TARP γ8-Containing AMPA Receptors as a Novel Therapeutic Approach for Chronic Pain.

Knopp KL, Simmons RMA, Guo W, Adams BL, Gardinier KM, Gernert DL, Ornstein PL, Porter W, Reel J, Ding C, Wang H, Qian Y, Burris KD, Need A, Barth V, Swanson S, Catlow J, Witkin JM, Zwart R, Sher E, Choong KC, Wall TM, Schober D, Felder CC, Kato AS, Bredt DS, Nisenbaum ES.

J Pharmacol Exp Ther. 2019 Jun;369(3):345-363. doi: 10.1124/jpet.118.250126. Epub 2019 Mar 25.

PMID:
30910921
2.

The α2,3-selective potentiator of GABAA receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in rats.

Witkin JM, Cerne R, Davis PG, Freeman KB, do Carmo JM, Rowlett JK, Methuku KR, Okun A, Gleason SD, Li X, Krambis MJ, Poe M, Li G, Schkeryantz JM, Jahan R, Yang L, Guo W, Golani LK, Anderson WH, Catlow JT, Jones TM, Porreca F, Smith JL, Knopp KL, Cook JM.

Pharmacol Biochem Behav. 2019 May;180:22-31. doi: 10.1016/j.pbb.2019.02.013. Epub 2019 Feb 27.

PMID:
30825491
3.

Extracellular signal-regulated kinases mediate the enhancing effects of inflammatory mediators on resurgent currents in dorsal root ganglion neurons.

Wu B, McDermott JS, Krajewski JL, Knopp KL, Nisenbaum ES, Cummins TR, Tan ZY.

Mol Pain. 2019 Jan-Dec;15:1744806919837104. doi: 10.1177/1744806919837104.

4.

Role of intraganglionic transmission in the trigeminovascular pathway.

Zhang L, Kunkler PE, Knopp KL, Oxford GS, Hurley JH.

Mol Pain. 2019 Jan-Dec;15:1744806919836570. doi: 10.1177/1744806919836570.

5.

Experimental design and reporting standards for improving the internal validity of pre-clinical studies in the field of pain: Consensus of the IMI-Europain consortium.

Knopp KL, Stenfors C, Baastrup C, Bannon AW, Calvo M, Caspani O, Currie G, Finnerup NB, Huang W, Kennedy JD, Lefevre I, Machin I, Macleod M, Rees H, Rice ASC, Rutten K, Segerdahl M, Serra J, Wodarski R, Berge OG, Treede RD.

Scand J Pain. 2015 Apr 1;7(1):58-70. doi: 10.1016/j.sjpain.2015.01.006.

PMID:
29911603
6.

Broad spectrum efficacy with LY2969822, an oral prodrug of metabotropic glutamate 2/3 receptor agonist LY2934747, in rodent pain models.

Johnson MP, Muhlhauser MA, Nisenbaum ES, Simmons RM, Forster BM, Knopp KL, Yang L, Morrow D, Li DL, Kennedy JD, Swanson S, Monn JA.

Br J Pharmacol. 2017 May;174(9):822-835. doi: 10.1111/bph.13740. Epub 2017 Mar 13.

7.

An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis.

Svensson KA, Heinz BA, Schaus JM, Beck JP, Hao J, Krushinski JH, Reinhard MR, Cohen MP, Hellman SL, Getman BG, Wang X, Menezes MM, Maren DL, Falcone JF, Anderson WH, Wright RA, Morin SM, Knopp KL, Adams BL, Rogovoy B, Okun I, Suter TM, Statnick MA, Gehlert DR, Nelson DL, Lucaites VL, Emkey R, DeLapp NW, Wiernicki TR, Cramer JW, Yang CR, Bruns RF.

J Pharmacol Exp Ther. 2017 Jan;360(1):117-128. Epub 2016 Nov 3.

8.

Pharmacological interrogation of a rodent forced ambulation model: leveraging gait impairment as a measure of pain behavior pre-clinically.

Adams BL, Guo W, Gors RT, Knopp KL.

Osteoarthritis Cartilage. 2016 Nov;24(11):1928-1939. doi: 10.1016/j.joca.2016.05.022. Epub 2016 Jul 19.

9.

TRPV3 in Drug Development.

Broad LM, Mogg AJ, Eberle E, Tolley M, Li DL, Knopp KL.

Pharmaceuticals (Basel). 2016 Sep 9;9(3). pii: E55. doi: 10.3390/ph9030055. Review.

10.

Synthesis and pharmacological characterization of C4-disubstituted analogs of 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: identification of a potent, selective metabotropic glutamate receptor agonist and determination of agonist-bound human mGlu2 and mGlu3 amino terminal domain structures.

Monn JA, Prieto L, Taboada L, Pedregal C, Hao J, Reinhard MR, Henry SS, Goldsmith PJ, Beadle CD, Walton L, Man T, Rudyk H, Clark B, Tupper D, Baker SR, Lamas C, Montero C, Marcos A, Blanco J, Bures M, Clawson DK, Atwell S, Lu F, Wang J, Russell M, Heinz BA, Wang X, Carter JH, Xiang C, Catlow JT, Swanson S, Sanger H, Broad LM, Johnson MP, Knopp KL, Simmons RM, Johnson BG, Shaw DB, McKinzie DL.

J Med Chem. 2015 Feb 26;58(4):1776-94. doi: 10.1021/jm501612y. Epub 2015 Feb 5.

PMID:
25602126
11.

Protein kinase C enhances human sodium channel hNav1.7 resurgent currents via a serine residue in the domain III-IV linker.

Tan ZY, Priest BT, Krajewski JL, Knopp KL, Nisenbaum ES, Cummins TR.

FEBS Lett. 2014 Nov 3;588(21):3964-9. doi: 10.1016/j.febslet.2014.09.011. Epub 2014 Sep 19.

12.

A method to enhance the magnitude of tactile hypersensitivity following spinal nerve ligation in rats.

Simmons RM, Forster B, Guo W, Knopp KL.

J Neurosci Methods. 2014 Aug 15;233:50-3. doi: 10.1016/j.jneumeth.2014.06.001. Epub 2014 Jun 10.

PMID:
24928434
13.

Tetrodotoxin-resistant sodium channels in sensory neurons generate slow resurgent currents that are enhanced by inflammatory mediators.

Tan ZY, Piekarz AD, Priest BT, Knopp KL, Krajewski JL, McDermott JS, Nisenbaum ES, Cummins TR.

J Neurosci. 2014 May 21;34(21):7190-7. doi: 10.1523/JNEUROSCI.5011-13.2014.

14.

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.

Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, Forster BM, Wong CJ, Li X, Crile RS, Shaw DB, Sahr AE, Adams BL, Quimby SJ, Diaz N, Jimenez A, Pedregal C, Mitch CH, Knopp KL, Anderson WH, Cramer JW, McKinzie DL.

Neuropharmacology. 2014 Feb;77:131-44. doi: 10.1016/j.neuropharm.2013.09.021. Epub 2013 Sep 23.

PMID:
24071566
15.

Evolving cancer pain treatments: rational approaches to improve the quality of life for cancer patients.

Knopp KL, Nisenbaum ES, Arneric SP.

Curr Pharm Biotechnol. 2011 Oct;12(10):1627-43. Review.

PMID:
21466450

Supplemental Content

Loading ...
Support Center